Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board increased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 112.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 97,338 shares of the biotechnology company’s stock after purchasing an additional 51,569 shares during the period. Ontario Teachers Pension Plan Board owned about 0.07% of Arrowhead Pharmaceuticals worth $1,538,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,308 shares in the last quarter. CWM LLC raised its position in Arrowhead Pharmaceuticals by 134.3% during the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 2,523 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Arrowhead Pharmaceuticals by 29.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 1,214 shares in the last quarter. XTX Topco Ltd acquired a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth about $133,000. Finally, Cerity Partners LLC acquired a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth about $141,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the sale, the insider owned 212,122 shares of the company’s stock, valued at $7,424,270. This represents a 8.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders sold 50,000 shares of company stock valued at $1,525,000. 4.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. B. Riley raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Finally, Morgan Stanley upped their price target on shares of Arrowhead Pharmaceuticals from $29.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 12th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.38.

Arrowhead Pharmaceuticals Trading Up 0.3%

Arrowhead Pharmaceuticals stock opened at $41.26 on Monday. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $43.69. The company’s fifty day moving average price is $35.85 and its two-hundred day moving average price is $23.81. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The company has a market capitalization of $5.70 billion, a price-to-earnings ratio of -32.23 and a beta of 1.27.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.